Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence
- PMID: 15567424
- DOI: 10.1016/j.neuropharm.2004.08.019
Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence
Abstract
gamma-Hydroxybutyric Acid (GHB) is thought to be a weak partial agonist at the gamma-aminobutyric acid(B) Receptor (GABA(B)R), but the precise relationship of the GHB receptor (GHBR) to the GABA(B)R remains unclear. In order to test the hypothesis that the GHBR is not identical to the GABA(B)R, we conducted two groups of experiments. First, GABA(B)R subtype 1 (R1) and/or subtype 2 (R2) were over expressed in HEK 293 cells and membrane binding studies on the transfected cells done using [(3)H]GHB and [(3)H] (2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene) ethanoic acid ([(3)H]NCS-382). The latter is a specific antagonist at the GHB binding site. Second, [(3)H]GHB and [(3)H]NCS-382 autoradiographic binding studies were done on the brains of mice in which the gene for GABA(B)R1a was deleted. Such mice do not have a functioning GABA(B)R. There was no detectable specific [(3)H]GHB or [(3)H]NCS-382 binding in HEK 293 cells transfected with GABA(B)R1, R2, or R1/R2. Binding to [(3)H]CGP54626A, a high affinity GABA(B)R antagonist, was absent in GABA(B)R1a(-/-) mice. There was no difference in [(3)H]NCS-382 binding observed in the brains of GABA(B)R1a(-/-), GABA(B)R1a(+/-) or GABA(B)R1a(+/+) mice. Specific [(3)H]GHB binding was observed in the brain of GABA(B)R1a(-/-) mice but was significantly lower than in wild type mice. These data support the hypothesis that the GHB binding site is separate and distinct from the GABA(B)R.
Similar articles
-
GHB receptor targets in the CNS: focus on high-affinity binding sites.Biochem Pharmacol. 2014 Jan 15;87(2):220-8. doi: 10.1016/j.bcp.2013.10.028. Epub 2013 Nov 20. Biochem Pharmacol. 2014. PMID: 24269284 Review.
-
Succinic semialdehyde dehydrogenase deficiency: GABAB receptor-mediated function.Brain Res. 2006 May 23;1090(1):15-22. doi: 10.1016/j.brainres.2006.02.131. Epub 2006 May 2. Brain Res. 2006. PMID: 16647690
-
Binding characteristics of the gamma-hydroxybutyric acid receptor antagonist [(3)H](2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene) ethanoic acid in the rat brain.J Pharmacol Exp Ther. 2001 Dec;299(3):1148-53. J Pharmacol Exp Ther. 2001. PMID: 11714906
-
Characterization and pharmacology of the GHB receptor.Ann N Y Acad Sci. 2008 Oct;1139:374-85. doi: 10.1196/annals.1432.048. Ann N Y Acad Sci. 2008. PMID: 18991884
-
A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor.CNS Drug Rev. 2004 Fall;10(3):243-60. doi: 10.1111/j.1527-3458.2004.tb00025.x. CNS Drug Rev. 2004. PMID: 15492774 Free PMC article. Review.
Cited by
-
Baclofen and gamma-hydroxybutyrate withdrawal.Neurocrit Care. 2008;8(3):430-3. doi: 10.1007/s12028-008-9062-2. Neurocrit Care. 2008. PMID: 18266111 Free PMC article.
-
Cognitive Impairment Following Clinical or Recreational Use of Gammahydroxybutyric Acid (GHB): A Systematic Review.Curr Neuropharmacol. 2022;20(4):809-819. doi: 10.2174/1570159X19666210610094352. Curr Neuropharmacol. 2022. PMID: 34151766 Free PMC article.
-
Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.J Inherit Metab Dis. 2007 Jun;30(3):279-94. doi: 10.1007/s10545-007-0574-2. Epub 2007 Apr 24. J Inherit Metab Dis. 2007. PMID: 17457693
-
Behavioral analyses of GHB: receptor mechanisms.Pharmacol Ther. 2009 Jan;121(1):100-14. doi: 10.1016/j.pharmthera.2008.10.003. Epub 2008 Oct 29. Pharmacol Ther. 2009. PMID: 19010351 Free PMC article. Review.
-
Comparison of N-methyl-2-pyrrolidone (NMP) and the "date rape" drug GHB: behavioral toxicology in the mouse model.Psychopharmacology (Berl). 2021 Aug;238(8):2275-2295. doi: 10.1007/s00213-021-05852-5. Epub 2021 Apr 21. Psychopharmacology (Berl). 2021. PMID: 33881584
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous